
Aridis Pharmaceuticals ARDS
Quartalsbericht 2023-Q3
hinzugefügt 06.11.2023
Aridis Pharmaceuticals Zahlungsmittel 2011-2026 | ARDS
Zahlungsmittel Jährlich Aridis Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.88 M | 18.1 M | 8.23 M | 20.9 M | 24.2 M | 25.1 M | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 25.1 M | 4.88 M | 16.9 M |
Zahlungsmittel Vierteljährlich Aridis Pharmaceuticals
| 2023-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 35 K | 4.88 M | 3.13 M | 6.32 M | 12.5 M | 18.1 M | 18.7 M | 4.09 M | 10.5 M | 8.23 M | 8.23 M | 8.23 M | 8.23 M | 20.9 M | 20.9 M | 20.9 M | 20.9 M | 24.2 M | 24.2 M | 24.2 M | 24.2 M | 25.1 M | 25.1 M | 25.1 M | - | 22.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 25.1 M | 35 K | 15.6 M |
Zahlungsmittel anderer Aktien in der Pharmaeinzelhändler
| Name | Zahlungsmittel | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M | ||
|
Amgen
AMGN
|
9.13 B | $ 349.77 | 0.57 % | $ 188 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
170 M | $ 19.23 | -1.38 % | $ 899 M | ||
|
Altimmune
ALT
|
43.8 M | $ 3.44 | 2.99 % | $ 303 M | ||
|
Autolus Therapeutics plc
AUTL
|
240 M | $ 1.4 | 2.19 % | $ 357 M | ||
|
Aytu BioScience
AYTU
|
31 M | $ 2.63 | 0.77 % | $ 16.5 M | ||
|
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M | ||
|
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
616 M | $ 218.06 | -1.72 % | $ 5 B | ||
|
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | ||
|
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M | ||
|
Benitec Biopharma
BNTC
|
97.7 M | $ 11.19 | 1.91 % | $ 461 M | ||
|
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
345 K | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | ||
|
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
12.9 M | - | 10.36 % | $ 9.8 M | ||
|
Compugen Ltd.
CGEN
|
7.8 M | $ 2.09 | - | $ 195 M | ||
|
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
3.33 M | $ 0.61 | -1.3 % | $ 6.99 M | ||
|
Avenue Therapeutics
ATXI
|
2.59 M | - | -52.27 % | $ 4.45 M | ||
|
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | ||
|
Cellectis S.A.
CLLS
|
61.5 M | $ 3.42 | 2.4 % | $ 116 M | ||
|
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M | ||
|
Cullinan Management
CGEM
|
88.3 M | $ 12.84 | 0.78 % | $ 774 M | ||
|
Atreca
BCEL
|
30.8 M | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
112 M | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
4.55 B | - | 0.49 % | $ 251 B | ||
|
Calithera Biosciences
CALA
|
59.5 M | - | -10.95 % | $ 876 K | ||
|
CorMedix
CRMD
|
145 M | $ 6.42 | 2.72 % | $ 462 K | ||
|
Cara Therapeutics
CARA
|
51.8 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
50 M | - | - | $ 3.74 B | ||
|
Bellerophon Therapeutics
BLPH
|
6.92 M | - | -74.18 % | $ 955 K | ||
|
Checkpoint Therapeutics
CKPT
|
6.6 M | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
143 M | - | -7.23 % | $ 13 M | ||
|
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | ||
|
Denali Therapeutics
DNLI
|
175 M | $ 21.09 | 4.56 % | $ 3.47 B | ||
|
Dyadic International
DYAI
|
6.52 M | $ 0.86 | -8.51 % | $ 24.8 M | ||
|
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
26.3 M | $ 4.42 | 4.25 % | $ 734 M | ||
|
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | ||
|
AIkido Pharma
AIKI
|
4.08 M | - | 1.93 % | $ 17.4 M |